Connect with us

Health

AI Saves Clinicians Weeks of Work but Health Systems Struggle to Keep Up, Philips Report Finds

Published

on

Healthcare professionals are gaining significant time savings through artificial intelligence tools, but health systems are struggling to adapt quickly enough to the rapid pace of change, according to a new global report.

The findings come from the Future Health Index 2026 report published by health technology company Philips, which examined how AI is being used across hospitals and clinics and its impact on clinical workflows.

The study surveyed more than 2,000 clinicians and over 20,000 patients across 10 countries, including the United Kingdom, United States, Germany, France, China and India. It found that AI adoption among healthcare workers has increased significantly over the past year, with growing confidence in its ability to improve patient care.

More than 80% of healthcare professionals said they are optimistic about AI’s impact on patient outcomes, while around 70% believe the benefits already outweigh the risks. Many clinicians reported that AI is already making a measurable difference in their daily work.

According to the report, 46% of clinicians said they save at least 132 hours per year through AI-enabled tools, equivalent to more than three working weeks. Nurses were among those reporting the greatest time savings, particularly from reduced administrative workloads.

Shez Partovi, Chief Innovation Officer at Philips, said clinicians are increasingly able to redirect that time toward patient care, collaboration and reflection on complex medical cases. He noted improvements in work-life balance, reduced stress and greater efficiency across clinical teams.

Around 71% of respondents said AI has improved workflow efficiency, while half said it has allowed them to see more patients. Approximately the same proportion reported better work-life balance and lower stress levels.

See also  Toxic ‘Forever Chemicals’ Found in Reusable Menstrual Products, Raising Health Concerns

Common uses of AI include transcribing medical notes, scheduling appointments and assisting with diagnostic tasks such as reviewing X-rays. Some clinicians also described using AI systems as support tools for clinical discussions and decision-making, including identifying potential drug interactions.

The report also found that 39% of clinicians had seen AI help identify or prevent potential medical errors multiple times in recent months, while more than 65% said it had improved their confidence in clinical decisions.

Despite these gains, the report highlights growing pressure on health systems to keep pace with demand for AI tools. Nearly two-thirds of clinicians said they turn to personal AI applications when workplace systems are insufficient, raising concerns about governance and data security.

Seven in 10 respondents said training for AI tools is limited or inconsistent, suggesting organisations are struggling to implement structured adoption programmes. Partovi said this reflects a gap between rapid technological advancement and slower institutional rollout.

He added that hospitals face complex challenges including privacy, safety, regulatory oversight and role-specific training, all of which must be addressed to ensure safe deployment.

Looking ahead, 96% of healthcare professionals expect AI to change their roles, with more than half anticipating major shifts in how they work. However, concerns remain, with 44% worried about losing clinical skills due to over-reliance on AI and 37% saying changes are happening faster than they are comfortable with.

Even so, most clinicians emphasised that human oversight remains essential. Around 86% said AI outputs must always be reviewed by healthcare professionals, while more than 80% said technology will not replace the patient-clinician relationship.

See also  Study Warns Aid Cuts Could Cause Millions of Preventable Deaths by 2030

Health

Portuguese Teenagers Report Lower Drug and Alcohol Use, but High-Risk Behaviour Persists

Published

on

Portuguese teenagers are reporting lower levels of alcohol and drug use and fewer problems linked to addictive behaviours, but risks are becoming increasingly concentrated among young people facing multiple personal and social difficulties, according to a new study.

The findings come from the 2024 Study on Alcohol, Tobacco, Drugs and Other Addictive Behaviours (ECATD-CAD), conducted by the Institute for Addictive Behaviours and Dependencies (ICAD). The research examines addictive behaviours among pupils aged 13 to 18 attending state schools across Portugal.

Compared with the previous study in 2019, the latest results show a consistent decline in reported problems, including violence, accidents, hospitalisations, risky sexual behaviour and other incidents with potentially serious consequences.

Researchers linked the broader improvement to several protective factors. Students reported better academic performance, closer parental supervision and fewer nights out, suggesting that changes in family and school environments may be helping reduce risky behaviour.

However, ICAD warned that the overall decline does not mean the problem has disappeared. The most serious behaviours are increasingly concentrated in a relatively small group of adolescents who face greater individual and social vulnerabilities.

Recent alcohol consumption and, particularly, illicit drug use remain strongly associated with problematic situations. Young people who use psychoactive substances report higher rates of risky sexual behaviour, violence between individuals, accidents and trouble with the police.

The report noted that these problems do not necessarily occur immediately after substance use, but the association remains significant.

Combining alcohol with illicit drugs appears to carry additional risks. Adolescents who reported recent use of both substances experienced higher levels of accidents, police-related problems, cyberbullying and risky sexual behaviour than those who consumed alcohol alone.

See also  New Study Reveals How Coffee May Help Protect the Body From Ageing

Alcohol use also raises concerns about why some teenagers drink. While pleasure, entertainment and socialising remain the main motivations, a significant proportion said they consumed alcohol to forget their problems. ICAD identified this as a warning sign associated with potentially harmful drinking patterns and dependence.

Cannabis use presented a mixed picture. Although most users showed no indicators of dependency risk, the proportion classified as being at high risk increased, alongside growth in the group with no identified risk.

Social media remained the main concern among behaviours not involving substances. A significant number of young people acknowledged spending excessive time on these platforms. Indicators of problematic electronic gaming remained broadly stable, while gambling for money became more prevalent among adolescents, despite a slight decline in some indicators of problematic gambling.

The study also identified differences between boys and girls. Boys were more likely to report problems with the police, risky gaming and gambling. Girls reported higher levels of problematic social media use and were more likely to use alcohol to cope with emotional difficulties.

Family circumstances and wellbeing were also important. Low academic achievement, limited parental supervision, frequent nights out and poorer physical and emotional health were associated with greater risk. Better school performance, stronger parental involvement and improved wellbeing appeared protective.

Regional differences were also evident. Alentejo recorded the highest concentration of unfavourable indicators, followed by the Azores. Lisbon, which showed the greatest vulnerability in the 2019 study, no longer held that position.

ICAD’s findings point to the need for targeted support for vulnerable adolescents, even as overall patterns of substance use and related problems improve.

Continue Reading

Health

Plague Fears Return After Russian Death, but Europe Faces Very Low Risk

Published

on

The death of a scientist in Russia’s Siberian region of Irkutsk has revived concerns about plague, but health authorities say there is currently no evidence of an outbreak or sustained transmission in Europe.

The woman died from pneumonia of unknown origin, prompting speculation that she could have contracted pneumonic plague. Russian authorities have said no plague cases have been confirmed in the region, while tests conducted on people who had contact with the woman were negative.

The World Health Organization has asked Russia for additional information about the incident and offered assistance to local health authorities.

Plague is caused by the bacterium Yersinia pestis, which remains present in wild animal populations in parts of the world. It is commonly associated with rodents and the fleas that live on them. People can become infected through bites from infected fleas, contact with tissues or bodily fluids from infected animals, or respiratory particles from people suffering from pneumonic plague.

For Spain and most of Europe, however, the current risk is considered very low. The European Centre for Disease Prevention and Control says routine transmission has not been recorded in Europe for more than five decades.

That does not mean the bacterium has disappeared. Its continued presence in animal reservoirs means isolated human infections remain possible, particularly in areas where infected wildlife and fleas are found.

Spain has maintained epidemiological surveillance despite the absence of locally acquired cases for decades. In April 2026, its Public Health Commission updated the national plague protocol, including case definitions, epidemiological information and procedures for investigating suspected infections.

See also  Papua New Guinea Launches Emergency Polio Response After New Cases Detected

European authorities have also been monitoring the Siberian incident. The European Union discussed the case at a Health Security Committee meeting on October 7, while the ECDC said there was no evidence of secondary cases or sustained person-to-person transmission.

The WHO has assessed the risk to the European region as very low.

Plague continues to occur in parts of Africa, Asia and the Americas. According to the WHO, most reported human cases between 2019 and 2025 were concentrated in Madagascar and the Democratic Republic of the Congo. Madagascar records bubonic plague cases during its annual epidemic season, generally from September to April. In the United States, about seven human cases are reported each year, mainly in rural areas of western states.

The disease can occur in bubonic, pneumonic or septicaemic forms. Bubonic plague usually causes fever and painful swollen lymph nodes after an infected flea bite. Pneumonic plague affects the lungs and can spread between people through respiratory particles. Septicaemic plague occurs when the infection enters the bloodstream.

Modern antibiotics can successfully treat plague, but early diagnosis is critical. Health surveillance, rapid identification and treatment remain important in preventing isolated infections from developing into wider outbreaks.

Continue Reading

Health

Optogenetics Pioneers Win 2026 Nobel Prize in Medicine

Published

on

Scientists Karl Deisseroth, Peter Hegemann and Georg Nagel have been awarded the 2026 Nobel Prize in Physiology or Medicine for their work on light-gated ion channels and optogenetics, a technique that has transformed the study of the brain.

The Nobel Assembly at Karolinska Institutet announced the award on Monday, describing the work as laying the foundation for a new era in neuroscience.

Optogenetics allows researchers to control selected cells using light, effectively providing a remote switch that can turn specific cells on or off. The technique has enabled scientists to investigate how individual neurons and neural circuits influence behaviour in living animals.

The origins of the discovery date back to Hegemann’s research more than three decades ago. While studying the single-celled alga Chlamydomonas, which moves towards light, he sought to understand how the organism detects changes in illumination.

Hegemann focused on the alga’s eyespot, a small light-sensing structure on its surface. His research and subsequent experiments identified light-sensitive proteins known as channelrhodopsins.

Hegemann later worked with Nagel at the Max Planck Institute for Biophysics in Frankfurt. The researchers inserted genes from the algae into frog egg cells and human kidney cells, demonstrating that channelrhodopsin functions as a light-controlled ion channel.

When exposed to blue light, the channel can open within about 0.2 milliseconds. Positively charged ions then enter the cell, generating an electrical signal.

Deisseroth later adapted the discovery for neuroscience. He introduced the channelrhodopsin gene into rat nerve cells and showed that blue light could activate the cells and trigger nerve signals.

He subsequently used the technique in the brains of living mice, demonstrating that researchers could control specific groups of neurons with light. Experiments showed that stimulating selected neural circuits could produce physical responses, including movements of a mouse’s whiskers, or cause sleeping animals to wake.

See also  Study Links Gut Bacteria to Increased Risk of Insomnia

The method was named optogenetics in 2006 and has since become an important research tool in neuroscience.

Researchers now use it to establish direct links between neural activity and behaviour. By activating or silencing particular groups of cells, scientists can study circuits associated with fear, anxiety, reward, pain, thirst, attention and aggression.

The technique has also been used in research into conditions including depression, schizophrenia, anxiety, Alzheimer’s disease, Parkinson’s disease and epilepsy.

Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine, said the discovery provides opportunities to map the brain in ways researchers could previously only imagine.

Optogenetics has also moved beyond laboratory research. Scientists are testing its potential as a treatment for retinitis pigmentosa, a genetic disorder that causes blindness through the loss of light-sensitive retinal cells.

In experimental treatments, researchers introduce genes encoding light-sensitive proteins into surviving retinal cells. In some trials, patients using specialised light-emitting goggles have been able to regain partial vision and detect high-contrast objects.

The Nobel award recognises a discovery that has given researchers an unprecedented way to investigate the relationship between brain cells, neural circuits and behaviour.

Continue Reading

Trending